Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
The product will have its corresponding ^nstruction for use document updated in section "limitation - interference". among the list of pharmaceuticals causing falsely elevated digoxin values at concentrations of the recommended daily dose nabumetone and pentoxifylline were re-added and triamterene was removed. nabumetone and pentoxifylline are not new limitations. they were accidentally removed since last edition in june 2010.